Abstract Number: 2555 • ACR/ARHP Annual Meeting 2018
Ixekizumab Treatment Results in Rapid and Sustained Improvements in the Disease Activity Index for Psoriatic Arthritis (DAPSA) in Patients Naïve to Biologic Dmards or with Previous Inadequate Response to TNF Inhibitors
Background/Purpose: The DAPSA is a composite tool that assesses several domains of psoriatic arthritis (PsA) manifestations and was developed as a disease activity measure for…Abstract Number: 2602 • ACR/ARHP Annual Meeting 2018
Evolution of Patient Characteristics in the Era of Biological Treatment of Psoriatic Arthritis: 18-Year Belgian Experience from Leuven Spondyloarthritis Biologics Cohort (BioSPAR)
Background/Purpose: Biologicals revolutionized the management of PsA. Since the introduction of the first TNF inhibitor (TNFi) in the early 2000s, therapeutic options for PsA are…Abstract Number: 1564 • ACR/ARHP Annual Meeting 2017
Treatment Patterns, Survival and Long-Term Effectiveness of Biological Agents in Psoriatic Arthritis Patients
Background/Purpose: The incorporation of biological disease modifying drugs (b-DMARD) has substantially improved the outcome of patients with Psoriatic Arthritis (PsA). Our aim was to evaluate…Abstract Number: 4L • ACR/ARHP Annual Meeting 2016
Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose: To evaluate the efficacy, safety, and tolerability of guselkumab (GUS), a fully human monoclonal antibody against the p19 subunit of IL-23, in patients (pts)…Abstract Number: 1554 • ACR/ARHP Annual Meeting 2014
Early and Sustained Modified Psarc Response in Psoriatic Arthritis Patients Treated with Ustekinumab: Results from 2 Phase 3 Studies
Background/Purpose: We have previously reported the efficacy and safety results of ustekinumab (UST), an IL-12/23 p40 inhibitor, in patients with active psoriatic arthritis (PsA) up…
ACR Meeting Abstracts